Insect Baculovirus
Expression Service
From gene to purified protein using the baculovirus–insect cell expression system (BEVS). Designed for complex eukaryotic targets — kinases, multiprotein complexes, GPCRs, and secreted proteins — where bacterial systems fall short and mammalian timelines are prohibitive.
System Overview
Why Insect Baculovirus — and When It's the Right Choice
The baculovirus expression vector system (BEVS) is a mature eukaryotic platform that has underpinned vaccine and drug discovery pipelines for over three decades. It occupies a practical middle ground: more biologically relevant than E. coli, faster and less costly than stable mammalian cell line development.
Eukaryotic Post-Translational Modifications
Insect cells support phosphorylation, N- and O-glycosylation, myristoylation, and palmitoylation — critical modifications absent from prokaryotic systems that affect protein folding and biological activity.
High Expression Yields
The polyhedrin and p10 promoters are among the strongest known. BEVS routinely delivers yields in the range of tens to hundreds of milligrams per liter under optimized conditions — substantially above many transient mammalian formats.
Faster than Stable Cell Line Development
A typical baculovirus project runs 6–10 weeks from sequence to purified protein. There is no requirement for lengthy stable transfection or selection cycles as with CHO or HEK293 stable lines.
Scalable and Serum-Free Compatible
Insect cell culture adapts readily to suspension conditions and serum-free media. Expression can be scaled from small pilot flasks to bioreactor formats (tens to hundreds of liters) without re-engineering the upstream process.
Multi-Protein Complex Expression
Multiple genes can be co-expressed from a single recombinant baculovirus or via co-infection, making BEVS well-suited for assembling heteromeric complexes, virus-like particles (VLPs), and multi-subunit enzyme assemblies.
Inherent Safety Profile
Baculoviruses infect only arthropods and do not replicate in vertebrate cells, providing a strong intrinsic safety margin for manufacturing environments and downstream animal studies.
Best suited for
- Kinases and phosphoproteins requiring active-site integrity
- Membrane proteins, GPCRs, and ion channels (≤4 transmembrane domains with good success rates)
- Large proteins (>100 kDa) prone to truncation in E. coli
- Secreted proteins and glycoproteins
- Virus-like particle (VLP) production
- Structural biology targets (cryo-EM, X-ray crystallography)
- Multi-subunit complexes requiring co-expression
Consider alternatives when
- Authentic mammalian glycosylation patterns are essential (consider HEK293 or CHO)
- Rapid turnaround of small, simple, non-glycosylated proteins is the priority (E. coli may be sufficient)
- Regulatory submission requires GMP-grade mammalian-derived glycoforms
- Target protein has confirmed toxicity to Sf9/Hi5 host cells at high MOI
Why BioCrest Sci
Our Service Advantages
Capabilities built around the practical demands of structural biology, assay development, and early-stage drug discovery programs.
Codon Optimization & Protein Analysis
- We provide codon-optimization and post-expression protein analysis as part of the standard workflow, improving the probability of soluble, active protein at the first attempt.
Extensive Insect Cell Track Record
- Our team has accumulated substantial project experience in insect-cell expression, including challenging targets such as full-length membrane proteins with up to four transmembrane spans.
Multiple Fusion Tags & Host Options
- We support His, GST, Strep-II, FLAG, and MBP tags, and offer Sf9, Sf21, Hi5, and S2 host cell options to match the solubility and secretion profile of your target.
Multi-Scale Fermentation Formats
- From 500 mL pilot flasks to 2.5 L, 10 L, and 30 L scale-up, with large-scale bioreactor options at 80 L, 130 L, and 250 L for programs requiring gram-level quantities.
In-House Milligram-to-Gram Protein
- We can deliver high-purity recombinant protein at milligram to gram quantities within competitive lead times, reducing the need for multi-vendor handoffs.
Low Endotoxin — LAL Verified (<0.1 EU/µg)
- Endotoxin levels are verified by LAL assay to below 0.1 EU/µg, meeting requirements for cell-based functional assays, immunological studies, and in vivo preclinical work.
Production Workflow
Custom Recombinant Protein Production — Step by Step
Our end-to-end workflow follows the Bac-to-Bac® BEVS framework, with proprietary optimizations at each stage. Estimated project duration is 6–10 weeks from sequence submission to protein release, depending on target complexity and required scale.
Plasmid Construction
- Target gene codon-optimized for insect cell expression using algorithm-based tools
- Gene of interest (GOI) cloned into a baculovirus transfer vector (e.g., pFastBac™ series)
- Sequence verified by Sanger sequencing prior to downstream use
Recombinant Bacmid & High-Titer Virus Preparation
- Recombinant transfer vector transformed into DH10Bac competent cells
- GOI transposed into the baculovirus shuttle vector (bacmid) via Tn7-mediated transposition; positive clones selected by blue/white screening
- Sf9 or Hi5 cells transfected with purified bacmid DNA to generate P1 virus stock; amplified to high-titer P3 working stock
- Viral titer determined by plaque assay or qPCR before proceeding to expression
Scale-Up Expression & Purification
- Sf9 or Hi5 cells infected at optimized multiplicity of infection (MOI) in spinner flasks or bioreactor
- Cells or supernatant harvested at the empirically determined optimal time post-infection (h.p.i.) based on pilot expression data
- Primary capture by affinity chromatography (His-tag IMAC, GST resin, Strep-Tactin, or FLAG-agarose)
- Polishing by ion exchange chromatography (IEX) and/or size exclusion chromatography (SEC) as required for purity target
Additional Services (Optional Add-Ons)
- 0.22 µm filter-sterilization to reduce bioburden for cell-based applications
- Endotoxin removal by polymyxin B or activated charcoal; final level verified to <1 EU/mg by LAL assay (or <0.1 EU/µg per premium specification)
- Lyophilization with defined excipient formulation for enhanced long-term stability during shipping and storage
Quality Control & Release
- Purity assessed by SDS-PAGE and SEC-HPLC (target ≥90% purity for standard release)
- Protein concentration determined by A280 absorbance or BCA assay
- Endotoxin level verified (<1 EU/mg standard; <0.1 EU/µg available upon request)
- Functional activity assay (binding ELISA, enzyme activity, or thermal shift) performed where applicable and agreed at project initiation
- Certificate of Analysis (CoA) issued upon release; additional technical report provided for complex projects
Host Cell Lines
Protein Expression — Insect Host Cell Systems
We maintain multiple authenticated insect cell lines, each suited to specific expression contexts. Cell line selection is made in consultation with the project team based on your protein's properties and intended application.
| Cell Line | Origin | Primary Applications |
|---|---|---|
| Sf9 Most common | Isolated from Spodoptera frugiperda pupal ovarian tissue; derived from the IPLB-SF-21AE cell line | The most widely used host for BEVS. Suitable for transfection, recombinant baculovirus propagation, high-titer virus production, plaque assays, and intracellular or secreted recombinant protein expression. The industry-standard starting point for most projects. |
| Sf21 Structural targets | Parent line of Sf9; derived directly from S. frugiperda IPLB-SF-21 pupal ovarian cells | Functionally comparable to Sf9 for most applications including transfection, virus amplification, plaque purification, and recombinant protein expression. Sf21 can outperform Sf9 in certain structural protein contexts — notably crystallin proteins — where it may yield more homogeneous preparations. |
| Hi5 Secreted proteins | Derived from ovarian cells of Trichoplusia ni (cabbage looper moth) | Preferred host for secreted recombinant proteins due to a more active secretory pathway and typically higher extracellular yields relative to Sf9. Also used for recombinant virus-like particle (VLP) expression. Suitable for transfection and plaque purification, though generally considered secondary to Sf9 for routine virus propagation. |
| S2 Viral proteins | Derived from late-stage embryonic cells of Drosophila melanogaster; predominantly female tetraploid, with some diploid cells | Particularly well-suited for the recombinant expression of viral structural proteins and other targets that benefit from Drosophila-specific cellular machinery. Used as a stable expression system (inducible or constitutive) as well as for transient transfection in specialized research contexts. |
What You Receive
Standard Deliverables
Every project includes a defined deliverable package. Additional documentation or custom formulation can be discussed at project scoping.
Purified recombinant proteinTarget quantity agreed at project initiation; shipped in specified buffer at −80°C or lyophilized
Certificate of Analysis (CoA)Purity, concentration, endotoxin level, and relevant activity data
SDS-PAGE imageCoomassie or silver-stained gel showing major bands and purity estimate
SEC-HPLC chromatogramMonomer / aggregate profile under native-like conditions
Protein concentration reportA280 or BCA measurement with extinction coefficient used
Technical project reportProvided for complex or multi-round optimization projects; includes expression screening data, yield at each purification step, and QC summary
Ready to Discuss Your Protein Target?
Share your sequence, expression goals, and timeline. Our scientific team will assess feasibility and recommend the right host, tag, and scale before you commit.